Upgrade to SI Premium - Free Trial

Mira Pharma (MIRA)

0.95 -0.03 (3.06%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (9/2/26)

Latest Headlines

Form 8-K MIRA PHARMACEUTICALS, For: Jun 17 June 17, 2026 8:01 AM - SEC Filing MIRA Pharmaceuticals files Phase 2a trial protocol for CIPN drug June 17, 2026 8:00 AM - StreetInsider MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy June 17, 2026 8:00 AM - StreetInsider Form 4 MIRA PHARMACEUTICALS, For: Jun 12 Filed by: Shekhat Denil Nanji June 15, 2026 5:00 PM - SEC Filing Form 4 MIRA PHARMACEUTICALS, For: Jun 12 Filed by: Del Giudice Matthew Paul June 15, 2026 5:00 PM - SEC Filing Form 4 MIRA PHARMACEUTICALS, For: Jun 12 Filed by: MacPherson Edward Clouston June 15, 2026 5:00 PM - SEC Filing Form 4 MIRA PHARMACEUTICALS, For: Jun 12 Filed by: Whalen Matthew Pratt June 15, 2026 5:00 PM - SEC Filing Form 3 MIRA PHARMACEUTICALS, For: Jun 02 Filed by: Mushak Andriy June 9, 2026 5:00 PM - SEC Filing Form 8-K MIRA PHARMACEUTICALS, For: Jun 02 June 8, 2026 5:01 PM - SEC Filing MIRA Pharmaceuticals secures global rights to drug candidates June 4, 2026 8:02 AM - StreetInsider Form 8-K MIRA PHARMACEUTICALS, For: Jun 03 June 4, 2026 8:01 AM - SEC Filing MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 June 4, 2026 8:00 AM - StreetInsider Form 8-K MIRA PHARMACEUTICALS, For: May 21 May 27, 2026 8:01 AM - SEC Filing MIRA Pharmaceuticals expands Ketamir-2 licensing to worldwide rights May 27, 2026 8:00 AM - StreetInsider MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN May 27, 2026 8:00 AM - StreetInsider Form 10-Q MIRA PHARMACEUTICALS, For: Mar 31 May 14, 2026 3:04 PM - SEC Filing MIRA Pharmaceuticals reports positive Phase 1 results for Ketamir-2 May 14, 2026 8:01 AM - StreetInsider MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 May 14, 2026 8:00 AM - StreetInsider Form 8-K MIRA PHARMACEUTICALS, For: May 13 May 13, 2026 4:02 PM - SEC Filing MIRA Pharmaceuticals publishes peer-reviewed study on obesity drug candidate May 13, 2026 8:04 AM - StreetInsider MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate May 13, 2026 8:00 AM - StreetInsider Form 8-K MIRA PHARMACEUTICALS, For: May 12 May 13, 2026 7:31 AM - SEC Filing Form 4 MIRA PHARMACEUTICALS, For: Mar 30 Filed by: Aminov Erez April 1, 2026 5:00 PM - SEC Filing Form 10-K MIRA PHARMACEUTICALS, For: Dec 31 March 31, 2026 2:03 PM - SEC Filing MIRA Pharmaceuticals reports Mira-55 shows no CNS side effects in studies March 23, 2026 9:03 AM - StreetInsider Form 8-K MIRA PHARMACEUTICALS, For: Mar 23 March 23, 2026 9:02 AM - SEC Filing MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies March 23, 2026 9:00 AM - StreetInsider Full Article List